ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AMRX / forecast
ABVX (54) AXSM (35) ALKS (78) KNSA (71) ⌘ Pro Terminal →

Amneal Pharmaceuticals Inc. (AMRX) 12-Month Stock Forecast & Price Target Cone

$20.44 -4.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.31

Amneal Pharmaceuticals Inc. (AMRX) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (36.9% gross margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $7.49B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AMRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $20.44 (-4.97% 1D, market cap $7.49B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AMRX ranks #67 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AMRX compare to ABVX and AXSM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRX carries a Roarable B- (71/100 RQD), trailing P/E of 103.2x, gross margin of 36.9%, and ROIC of 14.1%. By comparison, ABVX (Abivax SA) holds a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMRX?
▼

Per AMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001723128), Amneal Pharmaceuticals Inc. generated $3.02B in revenue (+8.0% YoY), $72.1M in net income, and $269.9M in free cash flow against $3.68B in total assets and $2.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 103x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.31 (-0.65%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 8.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B-
025507510071
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B-
Cash (14)Whales (17)SEC (16)Macro (12)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+5.9% Base Target
$26 Bull$22 Base$17 Bear
📬 FREE AMRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMRX)Realized 20D OHLCV Swing Band: ±5.8%
Deterministic 5-Pillar Attribution (71/100 Composite)
🔍 WHY AMRX SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (24% of score)

20D Institutional Volume Accumulation (±5.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)

Altman Z-Score 3.83 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
63
Grade C+$18.90+6.9% Next Q
Q2 (-2Q)
66
Grade B-$20.20+4.7% Next Q
Q3 (-1Q)
68
Grade B-$21.14-3.3% Next Q
Current
71
Grade B-$20.44+6.8% Hist 90D α
Trajectory: C+ (63) → B- (71)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AMRX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, AMRX faces multiple-compression risk if 103.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 103x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 34.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($19.33) or 200D SMA ($15.86) invalidates the momentum regime and cuts Target Base ($21.64) toward Bear Floor ($16.76).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 71%NO 29%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your AMRX Position Size: $10,000

Shares at $20.44: 489.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $16.76
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $21.64
$10,587
+$587 (+5.9%)
12M Bull Case BreakoutTarget $25.54
$12,495
+$2,495 (+25.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$2374%A
Goldman SachsSector Coverage LeadBUY$2469%B
JP MorganUS Large-Cap ResearchHOLD$1958%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (AMRX Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AMRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.91%📐 HORIZONTAL RANGE
2026-11-03O $21.35H $21.51L $20.44C $20.44VOL 2.77M
RES: $22.82SUP: $16.64SMA50: $19.33SMA200: $15.86
$22.39$19.46$16.54$13.62$10.69RES $22.82SUP $16.64$20.442026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMRX Butterfly Map → + Track AMRX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMRX)

Health Care Rank #67 of 1015 ⚔️ ABVX vs AMRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMRX vs. ABVX, AXSM, ALKS, KNSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Amneal Pharmaceuticals Inc. (AMRX) ranks #67 by composite RQD confidence (71/100, grade B-) and #130 by equity capitalization ($7.49B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with AMRX at 71/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMRX ACTIVE
Amneal Pharmaceuticals Inc.
B- 71/100 103.2x 36.9% 14.1% -4.97% $7.49B Benchmark Subject
ABVX
Abivax SA
D+ 54/100 32.8x — 9.9% -1.94% $7.56B /abvx-vs-amrx →
AXSM
Axsome Therapeutics Inc.
D- 35/100 — — -21.9% -5.83% $7.57B /axsm-vs-amrx →
ALKS
Alkermes plc
B+ 78/100 31.5x 86.7% 14.0% -0.99% $7.61B /alks-vs-amrx →
KNSA
Kiniksa Pharmaceuticals International plc (Class A)
B- 71/100 129.9x 88.5% 9.9% -1.56% $7.25B /knsa-vs-amrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001723128 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amneal Pharmaceuticals Inc. (AMRX) reported GAAP revenue of $3.02B (+8.0% vs. FY2024 revenue of $2.79B , and +26.1% cumulative change since FY2023) , GAAP net income of $72.1M, operating cash flow of $340.0M, and free cash flow of $269.9M (+11.0% YoY). On the balance sheet, AMRX closed FY2025 with $3.68B in total assets against $2.57B in total debt (Altman Z-Score: 3.83, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.02B $72.1M $340.0M $269.9M $3.68B $2.57B
FY2024 (FY) 2024-12-31 $2.79B -$116.9M $295.1M $243.2M $3.50B $2.16B
FY2023 (FY) 2023-12-31 $2.39B -$84.0M $345.6M $237.9M $4.09B $957.0M

3. AMRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $20.44 (-4.97% 1D, market cap $7.49B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AMRX ranks #67 in composite RQD confidence.

How does AMRX compare to ABVX and AXSM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRX carries a Roarable B- (71/100 RQD), trailing P/E of 103.2x, gross margin of 36.9%, and ROIC of 14.1%. By comparison, ABVX (Abivax SA) holds a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMRX?

Per AMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001723128), Amneal Pharmaceuticals Inc. generated $3.02B in revenue (+8.0% YoY), $72.1M in net income, and $269.9M in free cash flow against $3.68B in total assets and $2.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 103x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMRX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMRX last traded at $20.44 (-4.97% on volume of 5,019,747 shares), positioning the stock +5.74% above its 50-day simple moving average ($19.33) and +28.88% above its 200-day simple moving average ($15.86). Across its 52-week range of $10.68 to $21.68, AMRX sits at the 88.7% percentile with a 14-day RSI of 66.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.8% ($19.25 to $21.63).

Direct Sub-Reports: AMRX RQD Cockpit AMRX 12M Forecast AMRX Earnings & Move AMRX Dividends & DRIP AMRX Insiders & 13F AMRX Whale Options AMRX Profit Sankey AMRX News & Why
ROARABLE RATING BRIEF • RQD 71/100 (B-) ✓ SEC XBRL & RQD VERIFIED

AMRX — Amneal Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Amneal Pharmaceuticals Inc. (AMRX) earns a live Roarable RQD composite score of 71/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $20.44 (-4.97% 1D, market capitalization $7.49B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 14.1%, gross margin of 36.9%, operating margin of 13.1%, and free cash flow yield of 3.63%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.08x equity beta, Altman Z-Score of 3.83, Piotroski F-Score of 9/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Amneal Pharmaceuticals Inc. Is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Specific product lines, customer base, and revenue model details are — The company's scale is reflected in its $7.44B market capitalization and reported FY 2025 revenue of $3.02B, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amneal Pharmaceuticals Inc. (AMRX) reported $3.02B in annual revenue (up from $2.79B in FY2024, +8.0% YoY) and $72.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.39B revenue, -$84.0M net income) through FY2025, AMRX scaled operating cash flow to $340.0M and free cash flow to $269.9M, backed by $3.68B in total assets against $2.57B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B- • RQD 71/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $10.68 – $21.68 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 103x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 103.2x trailing P/E and 21.4x EV/EBITDA against 13.1% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or bottleneck links are recorded (supply chain: NONE; butterfly links: empty). Specific upstream supplier and downstream customer relationships are — A prospective investor should monitor the Q3 earnings release and any valuation-driven volatility identified in the news feed, as these are the nearest-term signals in the available data.

  • Key Question #1: Can AMRX sustain or expand its 13.1% operating margin and 14.1% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.02B and free cash flow of $269.9M, how will capital allocation balance growth reinvestment against $2.57B in total debt?
  • Key Question #3: How sensitive is AMRX's 96.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

AMRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amneal Pharmaceuticals Inc. (AMRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AMRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMRX Bull vs. Bear Conversation Board — What's Your Call at $20.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AMRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $26.67 (+24.0%)
📌 Pinned Debate

Institutional whale-flow (18/20) and a strong forensic balance sheet (Altman Z 3.83, Piotroski F 9/9) support the B-grade Buy rating.

Here is why I am bullish on AMRX here at $21.51: Institutional whale-flow (18/20) and a strong forensic balance sheet (Altman Z 3.83, Piotroski F 9/9) support the B-grade Buy rating.. Compare AMRX's 13.1% operating margin and 14.1% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $20.43 are getting bought.

EarningsSniper 🐂 BULL

@ForensicBear Shorting a 17/20 institutional whale-flow stock at $21.51 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $16.35 (-24.0%)
Spot @ $21.51

Trailing P/E of 103.2 against a 2.4% net margin and $0.21 EPS leaves the stock priced for growth that the reported earnings do not yet

Trailing P/E of 103.2 against a 2.4% net margin and $0.21 EPS leaves the stock priced for growth that the reported earnings do not yet show.. Look at the math on AMRX: paying 103.2x trailing P/E for 14.1% ROIC and 13.1% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $18.93 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%